Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: A1chieve sub-analysis

Diabetes Therapy

Volumn 4, Issue 1, 2013, Pages 153-166

  Randeree, Hoosen ^a   Liebl, Andreas ^b   Hajjaji, Issam ^c   Khamseh, Mohammad ^d   Zajdenverg, Lenita ^e   Chen, Jian Wen ^f   Haddad, Jihad ^g  

^a Parklands Medical Centre   (South Africa)

^b Centre for Diabetes and Metabolism   (Germany)

^c National Centre for Diabetes and Endocrinology   (Libyan Arab Jamahiriya)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f Novo Nordisk FemCare AG   (Switzerland)

^g Division of Endocrinology Prince Hamazah Hospital   (Jordan)

Author keywords

A1chieve study; Bolus only; Insulin aspart; Oral glucose lowering drugs; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RISK ASSESSMENT; SCORING SYSTEM;

EID: 84899856134     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0026-y     Document Type: Article

References (31)

1. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond). 2005;18:29.
2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
4. Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes. 2012;3:110-7.
5. Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012;19:93-6.
6. International Diabetes Federation. Guideline for Management of PostMeal Glucose in Diabetes. Available at: http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf. Accessed 30 Aug 2012.
7. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12.
8. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-54.
9. Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40:641-59.
10. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a doubleblind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21:769-75.
11. Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc. 2009;109:26-36.
12. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780-8.
13. Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med. 2000;17:371-5.
14. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care. 1998;21:1904-9.
15. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med. 2000;17:762-70.
16. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801-5.
17. Perriello G, Pampanelli S, Porcellati F, et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med. 2005;22:606-11.
18. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41-6.
19. International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation; 2012.
20. Home P, Naggar NE, Khamseh M, et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res Clin Pract. 2011;94:352-63.
21. Scherbaum WA, Haak T. Medical antihyperglycaemic treatment of diabetes mellitus type 2. Update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes. 2009;117(9):522-57.
22. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30.
23. World Medical Association. Declaration of Helsinki-ethical principles for medical research involving human subjects 2008. Available at: http://www.riip-influenza.org/wp-content/uploads/2011/08/Helsinki-2008-EN.pdf. Accessed 8 Nov 2011.
24. International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). Revision 2, April 2007. Available at: http://www.pharmacoepi.org/resources/guidelines_08027.cfm. Accessed 22 May 2013.
25. The EuroQol Group: EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
26. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-108.
27. Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract. 2011;94:364-70.
28. Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and metaanalyses. Diabetologia. 2009;52:1990-2000.
29. Liebl A, Jones S, Goday A, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther. 2012;3:9.
30. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
31. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53:1258-69.